All Episodes

Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Rethinking the CLL Treatment Sequence: Guidance on Selecting and Sequencing Modern Treatment for Sustained Efficacy Across Lines of Therapy

Matthew D. Galsky, MD - Bladder Cancer Breakthroughs Unpacked: Practical Guidance on Bladder-Sparing Innovations, Perioperative Standards, and Multi-Targeted Platforms Across the Disease Spectrum

Vinod Ravi, MD, MS, MBA - Partnering Up to Facilitate Change in TGCT Care: Team-Based Tactics for Integrating Modern CSF1R Inhibitors in Clinical Practice

Guillermo Garcia-Manero, MD - MDS Connect: Community Questions, Expert Guidance, and Modern Treatment Principles in LR and HR Disease

Andrew J. Armstrong, MD, ScM, FACP - Continuing the Innovation Story in Prostate Cancer: Novel Advances and Therapeutic Expansions Across Disease Settings

Barbara Burtness, MD, FASCO - Innovation Takes the Stage in HNSCC: Immunotherapy and Novel Therapeutics in Locally Advanced and Recurrent/Metastatic Disease

Kathleen N. Moore, MD, MS, FASCO - Riding the ADC Wave Into Gynecologic Cancer Care: Evidence, Safety, and Precision Strategies

Fred Saad, CQ, MD, FRCS, FCAHS - Next-Generation Treatment Pathways in Prostate Cancer: Practical Case-Driven Guidance to Individualize Care

Andrew Kuykendall, MD - Ironing Out the Challenges of PV: Spotlight on Targeting the Hepcidin Pathway for Addressing Unmet Needs and Enhancing Patient Outcomes

Brendon M. Stiles, MD - The Immunotherapy Playbook for Resectable NSCLC: Real-World Challenges and Practical Strategies

Charise Gleason, MSN, NP-C, AOCNP / Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO - “Off-the-Shelf” Choices in RRMM: Oncology Nurse Guidance on Delivering Quality Care With BCMA and Non-BCMA Immunotherapy

Amy E. Armstrong, MD, Angela Hirbe, MD, PhD - ReiNForcing Care Pathways in NF1-PN: Solutions to Improve Outcomes Across the Patient Journey With MEK Inhibition and Shared-Care Models

Jason Westin, MD, MS, FACP, FASCO - Raising the CAP on Lymphoma Care: Community–Aligned Principles for Integrating CELMoDs Into Real-World Practice

Amandeep Salhotra, MD - An Immune Reset for AlloHCT Recipients: Updates on Engineered Cell Therapy for Improving Transplant Outcomes and Reducing GVHD

Eileen M. O'Reilly, MD, FASCO - Redefining Precision Oncology in Pancreatic Cancer: Translating Emerging KRAS-Targeted Strategies into Effective Clinical Management

Tiba Al Sagheer, PharmD, BCOP, BCACP, Amanda Yepes, PharmD, BCOP - Coordinating Transformative Care in NHL: Pharmacist Insights for Delivering CAR-T Therapy in the Era of Expanded Access and Therapeutic Innovation

Justin Arnall, PharmD, FCCP, BCOP / Anthony J. Perissinotti, PharmD, BCOP - Dispensing High-Quality Care for Myelofibrosis: Pharmacist Leadership in Delivering Effective JAKi Therapy

Sarah Hayward, PharmD, BCOP - Putting Pharmacist-Led Solutions Into Practice for Endometrial and Ovarian Cancer Care: Integrating Modern Therapies Into Personalized Treatment

Carl M. Gay, MD, PhD / Shelby L. Quinn, PharmD, BCOP - The 3 P’s of Pharmacist-Focused Care for DLL3-Targeting T-Cell Engagers in ES-SCLC: Plans, Protocols, and Patient Education

Ross Soo, MBBS, PhD, FRACP / Jonathan D. Spicer, MD, PhD, FRCSC - The Power of Personalised: Unlocking the Secrets of Individualised Management of Resectable EGFRm NSCLC

Guy Young, MD - Driving Innovation Forward in Hemophilia B With Gene Therapy: Clinical Conversations on Progress and Guidance on Practical Delivery

Shambavi Richard, MD / Joshua Richter, MD, FACP - Sorting the Sequence in Multiple Myeloma: Personalized Choices With BCMA and Non-BCMA Immunotherapies in Relapsed/Refractory Disease

Karim Fizazi, MD, PhD - Personalizing Care for Patients With Prostate Cancer: Collaborative Strategies for Modern Integration of Systemic Therapy

Sumanta Kumar Pal, MD, FASCO - Unlocking the Potential of Modern RCC Therapies: Expert Approaches to Tailoring Care and Optimizing Outcomes

Sara A. Hurvitz, MD, FACP - Key Steps to Success With CDK4/6 Inhibition in Early Through Metastatic Breast Cancer: Stratification, Selection, Sequencing, and Specialty Management

Jonathan W. Goldman, MD - Addressing un-MET Needs in NSCLC: Elevating MET-Targeting Options for Patients With a Poor Prognosis

Prof. Ciro Rinaldi, MD, PhD - Elevating Total Care for PV and ET: From Diagnostic Precision to Patient-Centred Innovation

Karen C. Daily, D.O. - RiskReady: A Systems Approach to Improving the Recognition and Treatment of High-Risk, HR+, HER2- Early Breast Cancer

Susana Banerjee, MBBS, MA, FRCP, PhD, Ana Oaknin, MD, PhD - Putting the Puzzle Together in Advanced Ovarian and Cervical Cancers: Translating Evidence Into Practice for Approved and Emerging ADCs

Erica L. Mayer, MD, MPH - Nurturing Lasting Benefits of Adjuvant CDK4/6 Inhibitor Therapy in High-Risk HR+, HER2- EBC: Best Practices for Patient Education, AE Monitoring and Management, and Enhanced Adherence/Persistence

Erica L. Mayer, MD, MPH - Risk Assessment and Treatment Initiation: Successfully Jumpstarting the Adjuvant CDK4/6 Inhibitor Treatment Journey in HR+, HER2- EBC

Haley A. Moss, MD, MBA / Angeles Alvarez Secord, MD, MHSc - Implementing Immuno-Oncology in Gynecologic Cancer Care for Veterans: Expert Insights on Personalized Treatment

Natasha B. Leighl, MD, MMSc, FRCPC, FASCO / Joshua Sabari, MD - Mastering the Evidence and Establishing Best Practices for Making Well-Informed Precision Decisions in EGFR-Mutated NSCLC

Erik P. Sulman, MD, PhD - Tumor Treating Fields as an Innovative Modality of Cancer Therapy: From CNS to Thoracic Malignancies and Beyond